Vir Biotechnology (VIR) Stock Soars on Early Omicron Testing Data

December 2, 2021 6:03 AM EST
Get Alerts VIR Hot Sheet
Price: $33.46 +0.97%

Rating Summary:
    5 Buy, 2 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 25 | Down: 19 | New: 35
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Shares of Vir Biotechnology (NASDAQ: VIR) are up nearly 9% after the company said that preliminary data shows that its sotrovimab cocktail, developed together with GlaxoSmithKline plc (NYSE: GSK), retains activity against Omicron.

Two companies said that sotrovimab showed it can protect against “all tested variants of concern”. VIR and GSK are now completing vitro pseudo-virus testing to confirm the cocktail’s protection against Omicron.

George Scangos, Ph.D., Chief Executive Officer of Vir, commented: “Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable."

Vir Biotechnology stock is up about 50% in recent days as investors bet sotrovimab can generate high sales as the world’s leading pharma companies race to offer protection against highly-mutated COVID variants.

A few days ago, H.C. Wainwright analyst Patrick Trucchio raised the price target on Vir Biotechnology to $200.00 (from $135.00) while maintaining a Buy rating. The new price target signals of over 300%.

"Several recent updates suggest to us that Vir and its collaboration partner GlaxoSmithKline (GSK; not rated) are likely to maintain a top-tier COVID-19 antiviral franchise, led at first by sotrovimab, an FDA EUA-authorized investigational single-dose intravenous (IV) infusion SARS-CoV-2 monoclonal antibody (mAb), for the foreseeable future,” the analyst said in a note.

VIR shares are trading more than 75% in the green YTD.

VIR stock is indicated to open at $51.00 today.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, FDA, Hot FDA News, Momentum Movers, Trader Talk

Related Entities

H.C. Wainwright, FDA